Business / Finance

RSS

Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility

FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc.

4 Mar 2025

Sphere Fluidics rebrands to Sphere Bio

Sphere Fluidics today announced its rebranding to Sphere Bio. The name change marks a significant milestone in the Company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions.

From Sphere Bio 26 Feb 2025

AZoNetwork honors women in STEM on the 10th anniversary of IDWGS

AZoNetwork is joining the global effort to close the gender gap.

11 Feb 2025

Boston Scientific announces agreement to acquire Bolt Medical, Inc.

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease.

From Boston Scientific 13 Jan 2025

AMF at SLAS 2025: Precision microfluidics in San Diego

AMF is excited to participate in the SLAS 2025 International Conference & Exhibition, taking place from January 25-29, 2025 at the San Diego Convention Center. This renowned event will bring together professionals from across the life sciences, biotech, and automation industries to showcase the latest innovations and technologies.

From Advanced Microfluidics SA 24 Dec 2024

New Optimer contract to develop bioanalytical tools for RNA therapy

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company.

From Aptamer Group 23 Dec 2024

bit.bio raises $30 million led by M&G Investments

bit.bio, the global leader in cell programming technology, today announced the successful closing of a $30 million financing round led by M&G Investments, a leading international savings and investment company.

18 Dec 2024

Fairjourney Biologics establishes Scientific Advisory Board

FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced it has established a Scientific Advisory Board (SAB) to support its strategy for ongoing growth and innovation.

16 Dec 2024

Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company

Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration to create a company focused on developing novel treatments for fibrosis.

12 Dec 2024

Newcells Biotech raises additional funding from investors

Newcells Biotech (“Newcells”), a leading drug discovery partner specializing in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today announced it has raised a further £1.2 m from existing investors Mercia Ventures, Northstar Ventures and North East Finance.

From Newcells Biotech 8 Dec 2024

evitria partners with Sapio Sciences to streamline antibody workflow management and reporting

Sapio Sciences, the science-aware™ lab informatics platform, today announced that evitria, a leader in antibody expression services, has selected Sapio’s Electronic Lab Notebook (ELN) and Sapio Report Builder to enhance its sample tracking, data capture, and reporting capabilities.

4 Dec 2024

AZoNetwork celebrates one billion page views

AZoNetwork, the Manchester-based scientific marketing and publishing platform, is celebrating one billion page views across its network of scientific websites.

From AZoNetwork UK Ltd. 26 Nov 2024

Sphere Fluidics strengthens global commercial teams and establishes direct sales and support channel in North America

Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for functional profiling of single cells at scale, today announced a significant expansion of its global commercial presence.

From Sphere Bio 14 Nov 2024

MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year.

From MaxCyte, Inc. 13 Nov 2024

Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study

Nomic Bio and PICI collaborate to quantify protein biomarkers in cancer immunotherapy, enhancing understanding of patient responses and treatment resistance.

From Nomic 12 Nov 2024

SfN 2024: Where neuroscience meets community, collaboration, and innovation

At SfN 2024, neuroscientists converge to share groundbreaking research, fostering interdisciplinary connections and advancing the understanding of the brain.

7 Nov 2024

Aptamer extends agreement with genetic medicines customer

Aptamer's Optimer technology achieves key milestones in genetic medicine delivery, enhancing targeting specificity and advancing towards preclinical studies.

From Aptamer Group 7 Nov 2024

Sciensus names Christian Tucat as Chief Executive Officer

With the appointment of Christian Tucat as CEO, Sciensus aims to leverage insights and expand its global reach in delivering lifesaving drugs and therapies.

From Sciensus 18 Oct 2024

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.

From Antiverse 16 Oct 2024

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.

From Ubiquigent Limited 16 Oct 2024